Q-omics provides the consensus-scored SCN7A profile across patient tissues and cancer cell-line models. SCN7A expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, SCN7A is differentially expressed in 16, with the highest sampling consensus in BLCA. Additionally, SCN7A protein abundance shows 24,619 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LUAD, BLCA, and GBM as cancer lineages where SCN7A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SCN7A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SCN7A survival associations across molecular data types. SCN7A RNA expression shows survival associations in the most cancer types (21), followed by mutation status (7) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SCN7A RNA expression–survival associations across cancer types. High SCN7A expression shows unfavorable associations in OV, BLCA, LUSC and LGG, but favorable associations in LUAD and BRCA. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify LUAD as the clearest survival context for SCN7A RNA expression.
This table summarizes SCN7A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for SCN7A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SCN7A shows lower tumor expression in BLCA, KIRC, LUAD, COAD, KIRP and LUSC. The BLCA box plot shows higher SCN7A RNA expression in normal versus tumor tissue (log2 FC = −3.077, t-test p < 0.001).
This table shows molecular features associated with SCN7A in patient tissues and cancer cell lines. In patient samples, SCN7A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SCN7A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LARGE_INTESTINE.
